BERG Appoints Narain To Chief Executive Officer; Haddock Joins As Chief Financial Officer/ Chief Operating Officer

BERG Hires Bristol-Myers Squibb Former Head of Finance

Feb 09, 2016, 09:02 ET from BERG

BOSTON, Feb. 9, 2016 /PRNewswire/ -- BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, has announced the appointment of Jason Haddock as Chief Financial Officer and Chief Operating Officer. Haddock brings to BERG over 20 years of experience in corporate finance, including 12 years in senior financial functions at pharmaceutical companies, as well as extensive global experience in business organizational management.

Haddock will report to Niven R. Narain, BERG's Chief Executive Officer, who was the founding President and Chief Technology Officer. A recognized expert and voice in the use of artificial intelligence in medicine and cancer systems medicine, Narain built the founding technology team, and has positioned BERG as a leader in precision medicine.

"As BERG scales its readiness and capabilities to lead the era of precision medicine and match patients to drugs based on their biology, we will usher a paradigm of putting the power back to the patient and physician," said Niven R. Narain. "Jason's wide breadth of expertise in worldwide finance and operations is the right fit to execute the operational plan and financial architecture for long-term sustainability."

Haddock is responsible for driving financial and cross-functional operations, leading teams and scaling the company's structures and processes to facilitate its growth trajectory. He joins BERG from Bristol-Myers Squibb, where he was Head of Finance for Worldwide Commercialization and Worldwide Medical shaping product strategy and performance. Jason has experience across commercial, medical and operational functions and well-versed on the nuances in the pharmaceutical landscape.  He is a proven change leader and has led organizational and business model transformations across the globe.  He is a Certified Management Accountant and holds a BS degree from Illinois State University and an EMBA from Washington University in St. Louis.

"We welcome Jason to BERG and are confident given his experience and drive, he will be able to catalyze our operational vision and embody the financial discipline that has enabled BERG to realize a robust pipeline built by world-class team," said Mitch Gray, Co-Founder and Director.

BERG, the namesake of Chairman and Co-founder Carl E. Berg, utilizes artificial intelligence as a foundation to creating the next generation of drugs and diagnostics. Its revolutionary drug, BPM 31510, has been engineered to battle some of the most deadly cancers, including highly metabolic tumors.

"Niven has been working in the capacity of CEO for some time -- I'm confident he has the management skills and technical knowledge to formally take on this role," said Carl E. Berg. "With Niven at the helm and paired with Jason, BERG is positioned to change the world and revolutionize the biotech and pharmaceutical industries. Niven is one of the few executives I've invested in who has the leadership, creativity, scientific, computer and software knowledge to accomplish this challenge."

Focused on a precision medicine approach to drug discovery, the company flips the normal drug development process by creating therapies that match the biology of a disease to produce the right treatment for a specific patient.  BERG's proprietary Interrogative Biology® Platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable data to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary, and governments with a data ecosystem for financial modeling of healthcare needs of the population.

About BERG
BERG, is a biopharmaceutical company with divisions that include Analytics, Pharma, Biosystems and Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, BERG is poised to realize its pursuit of a healthier tomorrow. For additional information, please visit www.BERGhealth.com.

About the BERG Interrogative Biology™ Platform  
BERG's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The BERG Interrogative Biology® platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.

Media Contact:
Christine Jackman
Ogilvy Public Relations
(646) 240-3425
Christine.Jackman@ogilvy.com

SOURCE BERG



RELATED LINKS

http://berghealth.com